West Pharmaceutical Services, Inc. (WST) experienced a tumultuous time based on information synthesized from various reports, with significant
stock sell-offs by insiders and investment entities like Victory Capital Management Inc, Fisher Asset Management LLC, Savant Capital LLC, and the Swiss National Bank. Conversely, firms including Benjamin F. Edwards & Company Inc, Van ECK Associates Corp, TCG Advisory Services LLC, and International Assets Investment Management LLC increased their holdings. WST faced better-than-expected Q1 and Q4 earnings, with beats on both revenue and earnings estimates. The company's financial performance was highlighted several times, with records of strong trading days despite underperforming competitors elsewhere.
CEO's sale of $24m worth of company stock is noteworthy and there were occasions where WST's stock underperformed competitors.
Financial results unveiled show
adjusted EPS rising amidst sales decline. Notably, WST received FDA 510(k) clearance for the Vial2Bag Advanced® 13mm Admixture Device. However, the company's financials have not caught up with its current share price, and lowered expectations from analysts were observed post latest results.
West Pharmaceutical Services WST News Analytics from Thu, 27 Jul 2023 07:00:00 GMT to Fri, 10 May 2024 10:04:03 GMT -
Rating -3
- Innovation 3
- Information 8
- Rumor -8
